A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
Key facts
- Who runs it
- Asian Institute of Gastroenterology, India
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 414 people, planned
- Started
- 20 Dec 2025
- Expected to end
- 12 Dec 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- Vonoprazan
- Esomeprazole 40mg
- Record updated
- 6 March 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Adults ≥18 years of age
- Endoscopically confirmed LA grade B, C, or D reflux esophagitis
- GERD symptoms (heartburn, regurgitation) for at least 4 weeks prior to enrollment
- Willing to provide informed consent and comply with study procedures
Who cannot take part
- Previous or ongoing treatment with Vonaprazan or Esomeprazole in the last 4 weeks
- Prior esophageal surgery or radiation therapy
- Use of NSAIDs, steroids, or anticoagulants affecting healing
- Barrett's esophagus, esophageal stricture, or malignancy
- History of PPI-refractory GERD or severe gastroparesis
- Significant hepatic or renal impairment (ALT/AST >3× ULN, eGFR <30 mL/min)
- Pregnant or breastfeeding women
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Gerd
This trial is currently available in India.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Primary Objective
Read full original descriptionShow less
• To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily.
Secondary Objectives
* To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events across treatment groups.
The 3 groups in the trial
- To determine whether Vonaprazon 10mg heals grade B esophagitis at 8 weeksOther group
Vonaprazon 10 mg heals gerd symptoms after 8 weeks
Treatment: Vonoprazan
- To determine whether Vonaprazon 20mg heals grade B esophagitis at 8 weeksOther group
Vonaprazon 20 mg heals gerd symptoms after 8 weeks
Treatment: Vonoprazan
- To determine whether esomeprazole 40mg heals grade B esophagitis at 8 weeksOther group
Esomeprazole 40mg heals gerd symptoms after 8 weeks
Treatment: Esomeprazole 40mg
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
- Criteria questions
- Built from NCT06953986, who can take part
- Record updated
- 6 March 2026